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Objective: The purpose of this study was to examine the outcome of patients in whom an infrainguinal bypass graft failed.
Methods: This was a retrospective analysis of consecutive patients undergoing infrainguinal bypass grafting in a single
institution over 8 years.
Results: Six hundred thirty-one infrainguinal bypass grafts were placed in 578 limbs in 503 patients during the study
period. The indication for surgery was limb-threatening ischemia in 533 patients (85%); nonautologous conduits were
used in 259 patients (41%), and 144 (23%) were repeat operations. After a mean follow-up of 28  1 months (median,
23 months; range, 0-99 months), 167 grafts (26%) had failed secondarily. The rate of limb salvage in patients with graft
failure was poor, only 50%  5% at 2 years after failure. The 2-year limb salvage rate depended on the initial indication
for bypass grafting: 100% in patients with claudication (n  16), 55%  8% in patients with rest pain (n  49), and 34%
 6% in patients with tissue loss (n  73; P < .001). The prospect for limb salvage also depended on the duration that
the graft remained patent. Early graft failure (<30 days; n 25) carried a poor prognosis, with 2-year limb salvage of only
25%  10%; limb salvage was 53%  5% after intermediate graft failure (<2 years, n  110) and 79%  10% after late
failure (>2 years, n  15; P  .04). Multivariate analysis revealed shorter patency interval before failure (P  .006), use
of warfarin sodium (Coumadin) postoperatively (P .006), and infrapopliteal distal anastomosis (P .01) as significant
predictors for ultimate limb loss.
Conclusion: The overall prognosis for limb salvage in patients with failed infrainguinal bypass grafts is poor, particularly
in patients with grafts placed because of tissue loss and those with early graft failure. (J Vasc Surg 2004;39:951-7.)Infrainguinal arterial reconstruction remains the treat-
ment of choice for critical limb ischemia and disabling
claudication.1 Although the initial results are almost always
favorable, subsequent graft failure remains a significant
clinical problem for the patient, surgeon, and health sys-
tem.2-9 Many reports have focused on the long-term results
of infrainguinal bypass grafting and the frequency of graft
failure, but few studies have specifically examined the con-
sequences and outcome of graft failure.10-13 This retro-
spective analysis was undertaken to evaluate limb salvage
after infrainguinal bypass graft failure and to identify factors
that may positively or negatively affect outcome.
METHODS
A retrospective review was performed of data for all
patients undergoing infrainguinal revascularization at the
University of Chicago Hospital from January 1994
through January 2002. Grafts implanted at other institu-
tions were not included in the analysis. The evaluation for
all patients included review of pertinent medical records,
history, focused examination including bilateral ankle-bra-
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Diagnostic angiography was used selectively, depending on
the availability and quality of accompanying radiographic
studies. Operative technique varied, given the inclusion of
seven vascular surgeons over the study period and no formal
attempt to fully standardize the approach. Target artery
selection varied with operative indication and availability;
above-knee targets were preferred in patients with claudi-
cation and rest pain, even if outflow was compromised.
Conduit choice was generally based on target artery avail-
ability; prosthetic conduits were preferred for above-knee
targets, and autologous vein for below-knee targets. A
variety of conduits and techniques were used in patients
with inadequate autologous vein, including use of prosthetic
grafts, with or without adjuncts such as vein patches or arte-
riovenous fistulas, and cyropreserved vein. Postoperative
anticoagulation was at the discretion of the operating sur-
geon, and may have included heparin, aspirin, warfarin,
and, more recently, clopidogrel. The specific treatment algo-
rithm for patients with failed bypasses was also at the discretion
of the surgeon; further attempts at limb salvage were un-
dertaken in patients at reasonable risk with salvageable feet.
Patient demographic data, indications, operative data,
complications, patency rates, limb salvage, and survival data
were tabulated, and all are reported in accordance with the
Society for Vascular Surgery–International Society for Car-
diovascular Surgery Ad Hoc Committee–recommended
definitions and standards for reports of lower extremity
ischemia.14 The term “failed graft” in this study specifically
refers to secondary failure of an infrainguinal arterial bypass
graft that was implanted at The University of Chicago
Hospital. Patients with failure of a graft created at an951
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cohort; they may have been included in the overall study if
a new graft was created as part of ongoing treatment, that
is, a repeat procedure.
Health Insurance Portability and Accountability Act
guidelines for patient inclusion and consent were observed,
and approval was obtained for database accrual and analysis.
Statistical analyses were performed with SPSS for Windows
software (SPSS Inc, Chicago, Ill). Patency, limb salvage,
and survival rates were calculated with life table methods.
Patient characteristics, indications, and procedure and graft
characteristics were compared for limb salvage with a log
rank test; the time to graft failure was used as a zero
reference point for the cohort of failed grafts. Characteris-
tics identified at univariate analysis as statistically significant
(P  .10) were further examined with a Cox proportional
hazards model. Those factors retaining significance at P 
.05 at multivariate analysis were considered independent.
RESULTS
Six hundred thirty-one consecutive infrainguinal by-
pass grafts were created in 578 limbs in 503 patients over
the study period. Demographic data are given in Table I.
Overall, there was a similar prevalence of coronary artery
disease (56%), previous coronary artery bypass grafting
(20%), and end-stage renal failure (18%) among patients
with both patent and failed grafts. Operative details are
given in Table II. Overall, 85% of operations were per-
formed for limb salvage, and 69% extended to infrapopliteal
target arteries. The grafts originated (inflow) from the
common femoral artery in 66% of procedures, the superfi-
cial femoral artery in 18%, the profunda femoris artery in
3%, the popliteal artery in 7%, and other arteries in 6%. The
distal target artery (outflow) was the above-knee popliteal
artery in 31% of procedures, the below-knee popliteal artery
in 11%, the tibioperoneal trunk in 3%, the anterior tibial
Table I. Demographic data for 503 patients undergoing
infrainguinal bypass grafting, and subset of patients (n 
102) with failed grafts
Total
patients (%)
(N  503)
Patients
with failed
grafts (%)
(n  102)
n % n %
Patient age (y) (mean  SD) 67 13 68 12
Hypertension 377 75 94 73
Coronary artery disease 282 56 79 62
Diabetes (any type) 269 54 59 46
Smoking (active or remote) 258 52 75 59
Female gender 249 50 79 55
Previous CABG 98 20 28 25
ESRD 90 18 26 17
COPD 46 9 12 9
CABG, Coronary artery bypass grafting; ESRD, end-stage renal failure,
maintained and hemodialysis; COPD, chronic obstructive pulmonary dis-
ease.artery in 19%, the posterior tibial artery in 18%, the pero-
neal artery in 14%, and the dorsalis pedis artery in 3%.
Twenty-three percent of operations were repeat proce-
dures, and nonautologous conduits were required in 41%.
Five-year results for the entire group are given in Fig 1
(mean follow-up, 28  1 months; median, 23 months;
range, 0-99 months). Five-year primary patency was 30%
5%, primary-assisted patency was 38%  6%, secondary
patency was 44% 6% (Table IV, online only), limb salvage
was 58%  3%, and patient survival was 70  4%.
At follow-up, 167 of the 631 grafts had failed second-
arily (26%), and this cohort was separated for further anal-
ysis. The overall prospect for 2-year limb salvage after graft
failure was 50%  5% (Table V, online only). Extended
limb salvage in extremities with failed grafts strongly de-
pended on the original indication for revascularization (Fig
2). No patient with claudication lost a limb after bypass
graft failure (n 16). In patients with rest pain, prolonged
salvage could still be achieved in about half of limbs (55%
8%) after 2 years. In contrast, patients with grafts initially
placed because of tissue loss had a high incidence of ampu-
tation after graft failure, and a 2-year limb salvage rate of
only 34%  6%. The differences in limb salvage in patients
operated on because of claudication, rest pain, or tissue loss
were highly statistically significant (P  .001).
Limb salvage also depended on the length of time the
graft remained patent (Fig 3). For this analysis, failed grafts
were separated into early (30 days), intermediate (30
days, 2 years) and late (2 years) failure categories, and
were evaluated for limb salvage from the time of failure.
Early failure carried a poor prognosis, with a 2-year limb
salvage rate of only 25% 10% after graft failure (n 25).
Limbs with grafts that failed in the intermediate term had a
better prognosis, with 2-year limb salvage in 53%  5% (n
 110). Finally, extremities in which grafts remained
patent for at least 2 years before failure enjoyed a salvage
rate of 79%  10% after graft failure (n  15). The
differences in limb salvage for grafts failing in the early,
intermediate, or late time intervals were statistically signif-
icant (P  .04). A particularly challenging patient group,
those with limb salvage indications (rest pain, tissue loss)
and early graft failure (30 days) exhibited a 2-year limb
salvage rate of only 10%  10% (n  22). Of note, 45 of
Table II. Operative details of 631 infrainguinal bypass
grafts and subset of failed grafts (n  167).
Total grafts
(N  631)
Failed grafts
(n  167)
n % n %
Limb salvage indication 533 85 146 87
Repeat operation 144 23 50 30
Above-knee target 194 31 44 26
Infrageniculate target 437 69 123 74
Autogenous conduit 371 59 78 47
Warfarin
anticoagulation
170 28 69 42
stand
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suitable candidates for repeat grafting, and underwent sub-
sequent ipsilateral bypass. This group exhibited a 2-year
limb salvage rate slightly superior to the overall cohort with
failed grafts (67%  8% vs 50%  5%).
Factors predictive of limb loss after failed grafting that
were found to be significant at P  .10 included original
indication for bypass grafting (P  .001), time interval of
patency before failure (P  .001), use of warfarin sodium
(Coumadin) (P .001), and infrapopliteal target artery (P
 .002; Table III). After multivariate Cox regression mod-
Fig 1. Cumulative survival, limb salvage, secondary pa
patients undergoing revascularization of 578 limbs with 6
of operation. All standard errors are less than 10%.
Fig 2. Cumulative limb salvage after failed infrainguinal
(n 16), rest pain (n 49), or tissue loss (n 73). Refe
the three curves is statistically significant (P  .001). Alleling, factors that retained significance included short pa-
tency interval before failure (P  .006), use of warfarin
postoperatively (P  .006), and infrapopliteal distal anas-
tomosis (P  .01).
DISCUSSION
The treatment of choice for symptomatic long-seg-
ment infrainguinal arterial occlusion is bypass grafting.1
The procedure has been used increasingly, and approxi-
mately 100,000 grafts are now created annually in the
United States.15 Owing to continued refinement in con-
, primary-assisted patency, and primary patency in 503
frainguinal bypass grafts. Reference point 0 is from time
s grafting in limbs revascularized because of claudication
point 0 is from time of graft failure. Difference between
ard errors are less than 10%.tency
31 inbypas
rence
cant
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ment, most patients undergoing infrainguinal bypass enjoy
a favorable immediate operative result.16 This has been
achieved despite clearly increasing comorbidity in patients
undergoing this operation.17 Although early patency is
routinely achieved, the life span of the graft is highly
variable, and a significant percentage of grafts fail in subse-
quent years.2-6,8,9,18,19 This attrition of functioning grafts
remains the most important and frustrating limitation of
the procedure.
Much attention has been directed toward optimizing
the technique and long-term results of infrainguinal bypass
Fig 3. Cumulative limb salvage after late graft failure (
24 months; n  110), and early graft failure (30 da
Difference between the three curves is statistically signifi
Table III. Predictive factors for limb loss after graft
failure (n  167)
Factor P
Indication (claudication vs rest pain vs tissue loss) .001
Interval of patency before failure (1 mo, 1-24 mo,
24 mo)
.001
Warfarin use .001
Infrapopliteal distal target .002
End-stage renal disease .113
Smoking .252
Age .280
Polytetrafluoroethylene conduit vs all others .321
Diabetes mellitus .350
Repeat operation .493
Cerebrovascular disease .612
Previous coronary artery bypass grafting .781
Hypertension .824
Chronic obstructive pulmonary disease .858
African American race .871
Coronary artery disease .892
Greater saphenous vein conduit vs all others .912grafting, and the pathophysiology and treatment of graft
failure is well-described.20-22 Less is known about the
consequences of graft failure and the prognosis for limb
salvage thereafter. The purpose of this study was to examine
the extended outcome in patients with infrainguinal graft
failure, irrespective of the subsequent treatment program.
For the 631 consecutive bypass grafts retrospectively re-
viewed in this study the 5-year primary patency rate was
30% 5%, the primary-assisted patency rate was 38% 6%,
the secondary patency rate was 44% 6%, the limb salvage
rate was 68%  3%, and patient survival was 70%  4%.
Most long-term patency rates in the literature have been
reported for selected conduit subgroups such as
single-segment autologous vein, ranging from 23% to
85%2,3,5-7,9,16,19,23-42; prosthetic grafts, ranging from 11%
to 39%4,18,24,32,33,43-48; and alternative autogenous con-
duits, such as arm vein, ranging from 31% to
63%2,19,25,43,49,50. Because the present series includes all
consecutive infrainguinal grafts, without subselection ac-
cording to conduit type or distal target, the patency rates
naturally fall somewhere between the traditionally favor-
able patency rates for autologous veins and unfavorable
patency rates for prosthetic conduits. This is also influenced
by long-term survival. Inasmuch as the 5-year survival of
70% in this series exceeds the survival rate in most other
studies,5,6,23,26,51,52 more patient-years were available for
late graft failure. The outcome of consecutive infrainguinal
bypass grafting procedures reported here reflects high inci-
dences of limb-threatening ischemia (85%), infrageniculate
target arteries (69%), prosthetic conduit use (41%), repeat
operations (23%), and end-stage renal disease (18%).
Of 631 grafts created during the study period, 167
(26%) failed secondarily at some point in their life span.
Among failed grafts there was a predictably high prevalence
onths; n 15), intermediate graft failure (30 days and
 25). Reference point 0 is from time of graft failure.
(P  .04). All standard errors are less than 10%.24 m
ys; n
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distal target arteries. The overall 2-year rate for salvage in
limbs with failed grafts was 50%, and was strongly depen-
dent on the original indication for bypass grafting. As
shown in Fig 3, no patient who received a bypass graft for
claudication lost the leg after the graft failed. It is well
known that claudication is not itself limb-threatening, and
the results of this study suggest that the leg is not further
jeopardized by an episode of graft failure. In contrast,
patients with rest pain or tissue loss fared poorly after graft
failure, with 2-year limb salvage rates of 55% and 34%,
respectively. Many of these extremities are “graft-depen-
dent,” and these data confirm that the operations are truly
performed for “limb salvage.”
Only a few reports have specifically measured outcome
after infrainguinal bypass graft failure, and most have fo-
cused on acute (30 days) failure only. Robinson et al10 in
1997 examined the results in 103 patients with early graft
failure, and found a 5-year secondary patency rate of only
23%, with a limb salvage rate of only 31%. Smaller cohorts
of acute graft failure were examined by Lombardi et al11
and Henke et al,12 with documented long-term limb sal-
vage rates of only 14% to 46%. Similar to these published
results, the current study includes 25 cases of early graft
failure, with subsequent 2-year limb salvage achieved in
only 25%. Clearly, early infrainguinal graft failure portends
a poor prognosis for limb salvage, and this should be borne
in mind when considering aggressive repeat operation for
early failure.
Less is known about the consequences of intermediate-
term or late graft failure and its implications for limb
salvage. As stated, limbs in which bypass grafts fail within
the first 30 days have a dismal prognosis for 2-year limb
salvage, only 25% in this series. In contrast, extremities that
can support bypass grafts for longer periods fare better,
even if they eventually fail. In this study, the chance for
salvage of an extremity that had supported a graft for up to
2 years was 53%, and a full 79% for extremities in which the
graft lasted more than 2 years. This is consistent with the
failure mode of bypass grafts in this interval being neointi-
mal hyperplasia, a process that slowly occludes the graft
while still enabling ongoing surveillance, collateral forma-
tion, and intervention when necessary. It also underscores
the importance of maintaining at least temporary graft
patency sufficient for healing of ischemic lesions and minor
amputations. A completely healed foot may enjoy extended
salvage, even in the event of graft failure. If intermediate-
term graft failure does result in the recurrence of lesions or
symptoms, the slow kinetics of neointimal hyperplasia often
preserves target arteries, and the patient can undergo re-
grafting if there is adequate conduit.
The two other statistically significant predictors of limb
loss after graft failure were an infrapopliteal target artery
and the use of warfarin postoperatively. The necessity of
distal bypass grafting reflects the severity of vascular occlu-
sion and the difficulty in repeat grafting; thus its inclusion is
not surprising. The finding that anticoagulation portends a
poor prognosis for limb salvage was not an expected result.It may indicate an independent contribution of anticoagu-
lation to limb loss, or may simply reflect the recognition of
a patient population at high risk for failure.
In summary, the overall prognosis for limb salvage in
patients with failed infrainguinal bypass grafts is poor,
particularly in patients with grafts placed because of
tissue loss or those with early graft failure. Considering
the strong relationship between duration of graft pa-
tency and limb salvage, efforts directed at monitoring
and maintaining bypass patency appear rational.
We thank Carolyn Firszt, MS, Senior Statistician, Ab-
bott Laboratories, for thoughtful review of the manuscript
and statistical methods.
REFERENCES
1. Mannick JA. Improved limb salvage from modern infrainguinal artery
bypass techniques. Surgery 1992;111:361-2.
2. Donaldson MC, Whittemore AD, Mannick JA. Further experience with
an all-autogenous tissue policy for infrainguinal reconstruction. J Vasc
Surg 1993;18:41-8.
3. Bergamini TM, George SM Jr, Massey HT, Henke PK, Klamer TW,
Lambert GE, et al. Intensive surveillance of femoropopliteal-tibial au-
togenous vein bypasses improves long-term graft patency and limb
salvage. Ann Surg 1995;221:507-16.
4. Burger DHC, Kappetein AP, van Bockel JH, Breslau PJ. A prospective
randomized trial comparing vein with polytetrafluoroethylene in above-
knee femoropopliteal bypass grafting. J Vasc Surg 2000;32:278-83.
5. Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass
with in-situ greater saphenous vein: long-term results using the Mills
valvulotome. Ann Surg 1991;213:457-65.
6. Watelet J, Soury P, Menard J-F, Plissonier D, Peillon C, Lestrat J-P, et
al. Femoropopliteal bypass: in situ or reversed vein grafts? Ten-year
results of a randomized prospective study. Ann Vasc Surg 1997;11:
510-9.
7. Anderson CB, Stevens SL, Allen BT, Sicard GA. In situ saphenous vein
for lower extremity revascularization. Surgery 1992;112:6-10.
8. Dalman RL, Taylor LM Jr. Infraiguinal revascularization procedures.
In: Porter JM, Taylor LM Jr, editors. Basic data underlying clinical
decision making in vascular surgery. St Louis (MO): Quality Medical
Publishing; 1994. p 141-3.
9. Belkin M, Knox J, Donaldson MC, Mannick JA, Whittemore AD.
Infrainguinal arterial reconstruction with nonreversed greater saphe-
nous vein. J Vasc Surg 1996;24:957-62.
10. Robinson KD, Sato DT, Gregory RT, Gayle RG, DeMasi RJ, Parent FN
III, et al. Long-term outcome after early infrainguinal graft failure. J
Vasc Surg 1997;26:425-38.
11. Lombardi JV, Doughterty MJ, Calligaro KD, Campbell FJ, Schindler
N, Raviola C. Predictors of outcome when reoperating for early infrain-
guinal bypass occlusion. Ann Vasc Surg 2000;14:350-5.
12. Henke PK, Proctor MC, Zajkowski PJ, Bedi A, Upchurch GR Jr,
Wakefield TW, et al. Tissue loss, early primary graft failure, female
gender, and a prohibitive failure rate of secondary infrainguinal arterial
reconstruction. J Vasc Surg 2002;35:902-9.
13. Dawson I, Keller BPJA, Brand R, Pesch-Batenburg J, van Bockel JH.
Late outcomes of limb loss after failed infrainguinal bypass. J Vasc Surg
1995;21:613-22.
14. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
15. Rutkow IM, Ernst CB. An analysis of vascular surgical manpower
requirements in the United States. J Vasc Surg 1986;3:74-83.
16. Whittemore AD, Donaldson MC, Mannick JA. Ten-year patency of
autogenous vein bypass grafts. In: Yao JST, Pearce WH, editors. Long-
term results in vascular surgery. Norwalk (CT): Appleton & Lange;
1993. p 243-6.
JOURNAL OF VASCULAR SURGERY
May 2004956 Baldwin et al17. Myers KA, Fuller JA, Scott DF, Devine TJ, Denton MJ, Chan A.
Multivariate Cox regression analysis of covariates for patency after
femorodistal bypass grafting. Ann Vasc Surg 1993;7:262-9.
18. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et
al. Six-year prospective multicenter randomized comparison of autolo-
gous saphenous vein and expanded polytetrafluoroethylene grafts in
infrainguinal arterial reconstructions. J Vasc Surg 1986;3:104-14.
19. Gentile AT, Lee RW, Moneta GL, Taylor LM Jr, Edwards JM, Porter
JM. Results of bypass to the popliteal and tibial arteries with alternative
sources of autogenous vein. J Vasc Surg 1996;23:272-80.
20. Donaldson MC, Mannick JA, Whittemore AD. Causes of primary graft
failure after in situ saphenous vein bypass grafting. J Vasc Surg 1992;
15:113-20.
21. Clowes AW. Intimal hyperplasia and graft failure. Cardiovasc Pathol
1993;2:179S-86S.
22. Idu M, Buth J, Hop W, Cuypers P, van de Pavoordt E, Tordoir J.
Factors influencing the development of vein-graft stenosis and their
significance for clinical management. Eur J Vasc Endovasc Surg 1999;
17:15-21.
23. Olojugba DH, McCarthy MJ, Reid A, Varty K, Naylor AR, Bell PR, et
al. Infrainguinal revascularisation in the era of vein-graft surveillance: do
clinical factors influence long-term outcome? Eur J Vasc Endovasc Surg
1999;17:121-8.
24. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroeth-
ylene, umbilical vein, and saphenous vein bypass grafts for femoro-
popliteal above-knee revascularization: a prospective randomized De-
partment of Veterans Affairs cooperative study. J Vasc Surg 2000;32:
268-77.
25. Ho¨lzenbein T, Pomposelli F, Miller A, Conteras M, Gibbons G, Camp-
bell D, et al. Results of a policy with arm veins used as the first alternative
to an unavailable ipsilateral greater saphenous vein for infrainguinal
bypass. J Vasc Surg 1996;23:130-40.
26. Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD.
Experience with in situ saphenous vein bypasses during 1981 to 1989:
determinant factors of long-term patency. J Vasc Surg 1991;13:1337-
49.
27. Mannick JA, Whittemore AD, Donaldson MC. Clinical and anatomic
considerations for surgery in tibial disease and the results of surgery.
Circulation 1991;83(suppl I):I-81-5.
28. Ballard JL, Killeen JD, Smith LL. Popliteal-tibial bypass grafts in the
management of limb-threatening ischemia. Arch Surg 1993;128:976-
81.
29. Tordoir JHM, van der Plas JPL, Jacobs MJHM, Kitslaar PJEHM.
Factors determining the outcome of crural and pedal revascularization
for critical limb ischemia. Eur J Vasc Surg 1993;7:82-6.
30. Biancari F, Alback A, Kantonen I, Luther M, Lepantalo M. Predictive
factors for adverse outcome of pedal bypasses. Eur J Vasc Endovasc Surg
1999;18:138-43.
31. Watson HR, Schroeder TV, Simms MH, Buth J, Horrocks M, Norgren
L, et al. Relationship of femorodistal bypass patency to clinical outcome.
Eur J Vasc Endovasc Surg 1998;17:77-83.
32. Jackson MR, Belott TP, Dickason T, Kaiser WJ, Modrall JG, Valentine
RJ, et al. The consequences of a failed femoropopliteal bypass grafting:
comparison of saphenous vein and PTFE grafts. J Vasc Surg 2000;32:
498-505.
33. Nasr MK, McCarthy RJ, Budd JS, Horrocks M. Infrainguinal bypass
graft patency and limb salvage rates in critical limb ischemia: influence of
the mode of presentation. Ann Vasc Surg 2003;17:192-7.34. Grimley RP, Obeid ML, Ashton F, Slaney G. Long-term results of
autogenous vein bypass grafts in femoropopliteal arterial occlusion. Br J
Surg 1979;66:723-6.
35. Harris PL, How TV, Jones DR. Prospective randomized clinical trial to
compare in situ and reversed saphenous vein grafts for femoropopltieal
bypass. Br J Surg 1987;74:252-5.
36. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein
bypass grafting: five-year results of a modern series. J Vasc Surg 1990;
11:193-206.
37. Taylor LM, Edwards JM, Porter JM, Phinnet ES. Reversed vein bypass
to infrapopliteal arteries. Ann Surg 1987;205:90-7.
38. Kent KC, Whittemore AD, Mannick JA. Short-term and midterm
results of an all-autogenous tissue policy for infrainguinal reconstruc-
tion. J Vasc Surg 1989;9:107-14.
39. Berkowitz HD, Greenstein S, Barker CF, Perloff LJ. Late failure of
reversed vein bypass grafts. Ann Surg 1989;210:782-6.
40. Rutherford RB, Jones DR, Bergentz S-E, Bergqvist D, Comerota AJ,
Dardik H, et al. Factors affecting the patency of infrainguinal bypass. J
Vasc Surg 1988;8:236-46.
41. Leather RP, Shah DJ, Chang BB. Resurrection of the in-situ saphenous
vein bypass: 1000 cases later. Ann Surg 1988;208:435-42.
42. Fogle MA, Whittemore AD, Couch N, Mannick JA. A comparison of in
situ and reversed saphenous vein grafts for infrainguinal reconstruction.
J Vasc Surg 1987;5:46-52.
43. Curi MA, Skelly CL, Woo DH, Desai TR, Katz D, McKinsey JF, et al.
Long-term results of infrageniculate bypass grafting using all-autoge-
nous composite vein. Ann Vasc Surg 2002;16:618-23.
44. Williams MR, Mikulin T, Lemberger J, Hopkinson BR, Makin GS.
Five-year experience using PTFE vascular grafts for lower limb isch-
emia. Ann R Coll Surg Engl 1985;67:152-5.
45. Charlesworth PM, Brewster DC, Darling RC, Robinson JG, Hallet JW.
The fate of polytetrafluoroethylene grafts in lower limb bypass surgery:
a six-year follow-up. Br J Surg 1985;72:896-9.
46. Whittemore AD, Kent KC, Donaldson MC, Couch NP, Mannick JA.
What is the proper role of polytetrafluoroethylene grafts in infrainguinal
reconstruction? J Vasc Surg 1989;10:299-305.
47. Moawad J, Gagne P. Adjuncts to improve patency of infrainguinal
prosthetic bypass grafts. Vasc Endovasc Surg 2003;37:381-6.
48. Klinkert P, van Dijk PJE, Breslau PJ. Polytetrafluoroethylene femo-
rotibial bypass grafting: 5-year patency and limb salvage. Ann Vasc Surg
2003;17:486-91.
49. Schulman ML, Badhey MR. Late results and angiographic evaluation of
arm veins as long bypass grafts. Surgery 1982;92:1032-41.
50. Chang BB, Darling RC III, Bock DEM, Shah DM, Leather RP. The use
of spliced vein bypass for infrainguinal arterial reconstruction. J Vasc
Surg 1995;21:403-12.
51. Faries PL, Pomposelli FB, Quist WC, LoGerfo W. Assessing the role of
gene therapy in the treatment of vascular disease. Ann Vasc Surg
2000;14:181-8.
52. Kalman PG, Johnston KW. Predictors of long-term patient survival after
in situ vein leg bypass. J Vasc Surg 1997;25:899-904.
Submitted Sep 18, 2003; accepted Jan 22, 2004.
Available online Mar 8, 2004.
Additional material for this article may be found online
at www.mosby.com/jvs.DISCUSSIONDr Peter K. Henke (Ann Arbor, Mich). That confirms what
we have found. A couple of years ago we presented a similar series
with all our failed grafts, and we found by multivariate regression
that tissue loss, female gender, and early primary failure predicted
about 100% need for amputation. My question is, In those pa-tients, and particularly those with early primary failure, do you
recommend amputation without a redo bypass? Second, in relation
to your last point, what is your graft surveillance duplex protocol,
and have you found that has made any impact, particularly for these
high-risk grafts?
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 5 Baldwin et al 957Dr. Zachary K. Baldwin. Recommendations for treatment of
early graft failure should naturally be tailored for the individual
patient, so it is difficult to make a general therapeutic recommen-
dation based on a single indicator such as early graft failure.
Nonetheless, it is interesting to note that when we specifically
analyzed those patients who had an initial indication of tissue loss
and early graft failure, their ultimate limb salvage was only 10% at
2 years post–graft failure. Hence these factors appear to be additive.
Gender was not specifically addressed as a variable in this
study, so I cannot comment on female patients being more prone
to limb loss after graft failure.
As to your second question, regarding graft surveillance, fol-
low-up has varied to some extent over the 8 years encompassed by
the study. Generally, patients are seen clinically within a monthpost-operation, and are studied with ultrasound at 3 months, 6
months, 9 months, and 1 year, and then annually thereafter.
Dr Timothy Baxter (Omaha, Neb). I have one quick ques-
tion, related to your conclusion. You suggest that since patients
who have limb loss have a shorter life span, if we kept the graft open
the patients may live longer. Are these patients dying because they
lose their graft, or are they losing their graft and getting amputa-
tions because they are dying?
Dr Baldwin. I believe that limb loss may certainly contribute
to poor survival, given the amputee’s restricted and sedentary
lifestyle, and propensity for infection, trauma, depression, and
need for frequent surgical interventions. This is a clinical obser-
vation only, however, and not specifically addressed by this
study.
